Kornimate/medical-research-clean huggingface dataset:
common genetic variation and type 2 diabetes

Conditions: Pre-diabetes

Summary: type 2 diabetes is a common metabolic disorder arising from a complex interaction between genetic predisposition and the environment. the development of this disorder is preceded by impaired glucose tolerance and elevated fasting glucose which also carry adverse cardiovascular risk. to date a few common genetic variants have been reliably associated with predisposition to type 2 diabetes. however, it is uncertain how these genes interact to alter insulin secretion and insulin action prior to the development of type 2 diabetes. we propose to utilize an established population-based cohort to determine how common genetic variants associated with type 2 diabetes alter the response to an oral glucose challenge in people without overt type 2 diabetes. this will enable us to understand how common variants alone or in combination alter whole-body glucose physiology and predispose to type 2 diabetes.


Eligibility criteria:
inclusion criteria: * fasting blood glucose \< 126mg/dl exclusion criteria: * fasting blood glucose \> 126mg/dl
feraccru® real world effectiveness study in hospital practice ( fresh )

Conditions: Anemia, Iron Deficiency; Inflammatory Bowel Diseases

Summary: the aim of the study is to understand the early experiences of feraccru® in patients with inflammatory bowel disease (ibd) and iron deficiency anaemia (ida) in the uk, including treatment effectiveness, patterns of use and tolerability.

the aim of the study is to understand the early experiences of feraccru® in patients with inflammatory bowel disease (ibd) and iron deficiency anaemia (ida) in the uk, including treatment effectiveness, patterns of use and tolerability. by describing the characteristics of patients treated with feraccru® and their outcomes, this study will provide the medical community with important information to support treatment decisions for their patients. this will ultimately support improvements to patient care, including the long-term outcomes of patients with ibd and ida

Eligibility criteria:
inclusion criteria: * male and female patients aged ≥ 18 years at the time of initiation . * patient presenting with mild to moderate ida that is secondary to either crohn's disease (cd) or ulcerative colitis (uc) defined as hb ≥9.5 g/dl and \<13.0 g/dl in males, or hb ≥9.5 g/dl and \<12.0 g/dl in females * serum ferritin concentration \<30 microgram/l or transferrin saturation of \<20% . * patient receiving feraccru® since the time of uk launch in june 2016. exclusion criteria: * patient receiving feraccru® as part of an interventional clinical trial. * patients with severely active ibd or requiring corticosteroids at the time of initiation on feraccru®. * patient with an ibd flare, as determined by the clinician. * patient with medical records that are not available for review. * patient not willing or unable to consent to study participation, or patient is deceased at the start of data collection period
vonafexor in patients with impaired renal function and suspected mash (metabolic dysfunction-associated steatohepatitis)

Conditions: Chronic Kidney Disease Stage 2; Chronic Kidney Disease Stage 3; Metabolic Dysfunction-Associated Steatohepatitis

Summary: this study is designed to establish the effect of 2 doses of vonafexor on the kidney. this will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (egfr) and suspected mash. in addition, the non-invasive multiparametric magnetic resonance imaging assessment of functional and structural changes in the kidney and in the liver will be investigated.

this is a phase 2, open-label, two-dose, randomized, parallel arms, single center study where subjects are participating for up to 32 weeks: * screening: 4 weeks * treatment: 16 weeks * follow-up: 12 weeks

Eligibility criteria:
inclusion criteria: * signed and dated informed consent obtained before any trial-related activities * male or female subject. * age between 18 and 75 years, both inclusive. * overweight or obesity (body mass index bmi ≥ 25.0 kg/m2 and ≤ 45.0 kg/m2) with or without type 2 diabetes mellitus (t2dm with an hba1c ≤ 9.5%). * egfr ≥ 30 and \< 90 (ml/min/1.73 m²). * presumed mild to higher liver fibrosis as shown by a fibrotest score ≥ 0.28 and/or fib-4 score ≥ 1.3. exclusion criteria: * known or suspected hypersensitivity to imp or any of the excipients or to any component of the imp formulation. * previous participation in this trial. participation is defined as randomised. * receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial. * history of multiple and/or severe allergies to drugs including contrast media or foods or a history of severe anaphylactic reaction. * known non-mash liver disease. * history or presence of cirrhosis (evidenced on imaging or by histology, or liver decompensation, including ascites, hepatic encephalopathy, or presence of esophageal varices). * total body weight loss of \>5% within 6 months prior to screening. * if female, pregnancy or breast-feeding. * women of childbearing potential who are not using a highly effective contraceptive method and whose male partner is not using a highly effective contraceptive method for the entire study duration and for at least 6 weeks after last dosing

Keywords: ckd chronic kidney disease mash metabolic dysfunction-associated steatohepatitis kidney function egfr estimated glomerular function rate mgfr measured glomerular function rate
oral verapamil in acute paroxysmal supra ventricular tachycardia(psvt) recurrence control

Conditions: Paroxysmal Supraventricular Tachycardia

Summary: psvt is a common rhythm disorder in emergency department which can be recurrent in some cases. intravenous adenosine is the drug of choice in psvt control in acute settings but is a very short acting agent. providing a complementary medication to decrease the rate of recurrence of psvt after its initial control will be promising. this study evaluates the role of the oral verapamil in recurrence control of psvt in emergency situations.


Eligibility criteria:
inclusion criteria: * age\>18 years old * psvt on emergency department presentation exclusion criteria: * instability in hemodynamic status * allergy to verapamil
a study to learn how renal impairment affects the pharmacokinetics of pf-07817883.

Conditions: COVID-19

Summary: the purpose of the study is to learn about: * how pf-07817883 is processed in the body of adult participants. * the safety of pf-07817883. these participants will have different levels of kidney function loss: * moderate * severe * none or healthy participants with moderate, severe or no loss of kidney function may be taken into one of 3 groups. this study is seeking for participants who: * are male or female of 18 to 90 years of age. * have different levels of damage to kidney function or for one of the groups, no damage * are willing to follow the requirements of the study including stay at clinic for 5 nights and 6 days. about, 8 participants may be selected in groups 2 and 3. in group 1, around 8 to 12 participants may be selected. if participants agree to take part in the study, it may take up to 4 weeks to complete all the tests to confirm if they are fit to be in the study. if they seem to be fit for the study, participants will be admitted to a clinic research unit (cru) at least 8 hours before dosing. on day 1, participants will receive a single amount of study medicine (day 1). a series of blood samples will be collected before and after giving medicines. participants will be discharged from the cru on day 5. a follow-up phone call (or cru visit, if needed), will occur 28-35 days after taking the medicine. the whole study will last for a minimum of 5 weeks and a maximum of 10 weeks.


Eligibility criteria:
inclusion criteria: * male or female participants aged 18 (or the minimum age of consent in accordance with local regulations) to 90 years of age at screening. * bmi of ≥16 kg/m2 and a total body weight \>45 kg (99 lbs). * stable renal function, defined as the egfr values obtained at the two screening visits should not be more than 25% different. exclusion criteria: * positive test result for severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection at the time of screening or day -1. * history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c; positive testing at screening for hiv, hepatitis b surface antigen (hbsag), hepatitis b core antibody (hbcab), or hepatitis c antibody (hcvab). as an exception, a positive hepatitis b surface antibody (hbsab) test due to hepatitis b vaccination is allowed. * renal transplant recipients. * any condition possibly affecting drug absorption

Keywords: renal impairment covid-19
bioequivalence study of mesylate imatinib capsule in chronic myeloid leukemia body

Conditions: Chronic Myeloid Leukemia

Summary: 1. purpose: to conduct the relative bioavailability study of a single dose and multiple doses of imatinib mesylate capsule (jiangsu chia-tai tianqing pharmacy co. ltd.) versus glivec (novartis pharma stein ag). 2. experimental design： two-period crossover design 3. test drug: imatinib mesylate capsule reference drug: glivec 4. sample size：20

to conduct the relative bioavailability study of a single dose and multiple doses of imatinib mesylate capsule(jiangsu chia-tai tianqing pharmacy co. ltd.) versus glivec (novartis pharma stein ag) and compare the bioequivalence and pharmacokinetics of the two products in 20 patients with chronic myeloid leukemia.

Eligibility criteria:
inclusion criteria: * patients with chronic myeloid leukemia; * age: 18-65 years,gender:both. * weight: standard weight ± 20% within, and avoid weight disparity is too large; * no previous radiation therapy, chemotherapy, or surgery within 1 weeks before treatment with imatinib; * performance status 0 to 3 (who scale); life expectancy greater than 3 months; * no other malignancy; * adequate hepatic, renal, and bone marrow function (wbc≥3.0×109/l，anc≥1.5×109/l，plt≥80×109/l. serum bilirubin≤1.5×the institutional upper limit of normal, alt、alp≤2.5×the institutional upper limit of normal, creatinine≤1.5×the institutional upper limit of normal); * ability to understand objectives of the study, the study procedure, the pharmacological properties of the drug and possible adverse reactions and the willingness to sign a written informed consent. exclusion criteria: * suffering from heart, liver, kidney disease or severe acute and chronic gastrointestinal diseases; * pregnant or lactating women and be sensitive to drug; * subjects are thought unsuitable for the study by investigators; * inability to comply with protocol or study procedures in the opinion of the investigator; * attending other clinical trials or attended other clinical trials 3 months ago.
intermittent bolus vs continuous infusion via esp catheters rct

Conditions: Post Operative Pain

Summary: the purpose of this prospective randomized controlled trial is to compare the effectiveness of two different delivery methods for postoperative pain management following cardiac surgery requiring median sternotomy: intermittent programmed la bolus versus continuous la infusion through esp catheters. effectiveness of analgesia will be assessed based on the subjects' nrs pain scores and opioid consumption. the primary outcome measure will be the patients' opioid consumption over the course of the 72 hours following surgery. secondary outcomes measures that will be evaluated include nrs pain scores, intensive care unit (icu) length of stay, and time to first dose of antiemetic in the postoperative period. it is hypothesized that the use of intermittent programmed la boluses will provide better analgesia compared to continuous la infusion through esp catheters. the findings of this study will provide guidance regarding the optimal method of delivery for postoperative pain management in patients following cardiac surgery.

the purpose of this prospective randomized controlled trial is to compare the effectiveness of two different delivery methods for postoperative pain management following cardiac surgery requiring median sternotomy: intermittent programmed la bolus versus continuous la infusion through esp catheters. effectiveness of analgesia will be assessed based on the subjects' nrs pain scores and opioid consumption. the primary outcome measure will be the patients' opioid consumption over the course of the 72 hours following surgery. secondary outcomes measures that will be evaluated include nrs pain scores, intensive care unit (icu) length of stay, and time to first dose of antiemetic in the postoperative period. it is hypothesized that the use of intermittent programmed la boluses will provide better analgesia compared to continuous la infusion through esp catheters. the findings of this study will provide guidance regarding the optimal method of delivery for postoperative pain management in patients following cardiac surgery.

Eligibility criteria:
inclusion criteria: * non-emergent elective cardiac surgery requiring median sternotomy for surgical exposure (i.e. cabg, aortic/mitral/tricuspid valve replacements) receiving esp catheter preoperatively * age 18-90 exclusion criteria: * placement and/or existence of cardiac assist devices (lvad, rvad, balloon pump, impella) * neurocognitive dysfunction * patients who expire before extubation * non-english speaking * daily opioid therapy prior to surgery * history of substance abuse * bmi \> 45
molecular characterisation of colorectal cancer peritoneal metastases

Conditions: Colorectal Cancer Metastatic

Summary: this project aims to characterise the tumour cell and tumour microenvironment of colorectal cancer peritoneal metastases, understand molecular changes leading to colorectal peritoneal metastasis, identify potential biomarkers and novel treatment strategies.

the peritoneum is the second most common site for recurrence in colorectal cancer (crc). cancer spread to the peritoneum (colorectal cancer peritoneal metastases, crpm) cause severe symptoms in patients and lead to shortened survival. the only definitive treatment available is a complex and aggressive surgical procedure involving radical removal of organs and the internal lining of the abdomen. the biology of crpm and correlations with clinical outcomes has been reported in small numbers of patients. there has been limited research on how extended cancer mutations lead to metastases and how this can affect treatment or survival. understanding how genetic mutations evolve in crpm and the role of the tumour microenvironment are important for optimising treatment and prevent the spread of cancer. this study proposes completing cancer genetic profiling on archived tissue removed routinely from patients who previously have had surgery for crpm. high through-put laboratory techniques for analysing the genetic profile of crc and crpm has the power to identify mutation patterns than might predict for treatments and survival outcomes. the results of genetic tests can then be compared to clinical characteristics, such as survival and treatments received. genes in primary colorectal cancer can be compared to those in crpm to describe what changes during the metastatic process. this study will help make progress towards better and personalised treatment options, identifying predictors of treatment success and long-term survival. improved treatments and better selection of patients may ultimately improve quality of life and help patients live longer.

Eligibility criteria:
participants are eligible to be included in the study only if all of the following criteria apply: 1. patients ≥ 18 years old who have been diagnosed with colorectal cancer and have colorectal peritoneal metastases, 2. have had cytoreductive surgery at the christie 3. have availability of archival tumour tissue (paired crc and crpm) exclusion criteria: * none

Keywords: colorectal cancer peritoneal metastatic
determination of baseline levels for prostate cancer-derived extracellular vesicles following local treatment of prostate cancer

Conditions: Prostate Carcinoma

Summary: this study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer.

primary objectives: i. determine the levels of prostate cancer-derived extracellular vesicles pre- and post-rp. ii. determine the correlation between levels of prostate cancer-derived extracellular vesicles and psa. outline: this is an observational study. participants are assigned to 1 of 2 cohorts. cohort i (radical prostatectomy): prostate cancer patients undergo blood and urine sample collection on study. patients' medical records are also reviewed. cohort ii (neoadjuvant): prostate cancer patients undergo blood and urine sample collection throughout the study. patients' medical records are also reviewed. cohort iii (negative controls): female urology clinic patients and female volunteers undergo blood and urine sample collection on study.

Eligibility criteria:
inclusion criteria: * \* prostate cancer patients: * age 18+ * able to give informed consent * patients with prostate cancer * patients treated with primary prostatectomy * the focus will be on high-risk patients with at least one of either criterion: * psa \>= 20 ng/ml * and/or gleason \>= 8 * and/or clinical stage \>= t3 * \* female control patients: * age 18+ * able to give informed consent exclusion criteria: * \* prostate cancer patients: * unable or unwilling to provide informed consent * metastatic prostate cancer - defined evidence of metastatic disease on pre-procedural testing * \* female control patients: * unable or unwilling to provide informed consent
international big data centre in emergency medicine

Conditions: Emergency Medicine

Summary: this observational study aims to use electronic health records to build an international big data centre in emergency medicine, within the institute of sciences in emergency medicine (isem) at the guangdong provincial people's hospital. the main questions it seeks to answer are not limited to the following: * identify the relationship between emergency department length of stay (edlos), mortality, and adverse events (ae) * identify the risk factors associated with high mortality and ae rate among patients who experience prolonged edlos * other research questions related to emergency medicine, such as building prediction and cluster models for acute diseases

the relationship between the emergency department length-of-stay (edlos), mortality, and adverse events (ae) rate remains unclear and underestimated. edlos is the time elapsed between the time of arrival and the time of the release of a patient admitted to ed. mortality is defined as short-term (14 hours, 48 hours, 7 days, 15 days) and 30 days death of patients managed in the ed discharged or admitted. an ae is an event that can result whether from medical mismanagement or happen by accident and causes physical and mental harm to the patient during the stay and remains after leaving. to separate the mismanagement from accidental causes i.e., compliant management but the unfortunate situation or persons, this study will refer to indicators that are objectively measurable and can be compared at different times throughout the patient's stay in the ed. the hypothesis is that a prolonged stay of the patients in the ed especially without diagnosis or decision of admission is associated with increased mortality and aes. this project will test this hypothesis through a prospective international multicenter study in contributing to whether a prolonged edlos is associated with an increased rate of adverse outcomes.

Eligibility criteria:
inclusion criteria: * every patient who ever visited emergency department from 2011-2022 exclusion criteria: * patients with missing demographic (age, gender, etc.) and triage data

Keywords: machine learning data mining artificial intelligence
surgical outcome at hfsuh

Conditions: Surgical Outcome

Summary: the study was conducted on already intervened hospital patients with surgical management and their final outcome was followed from the chart of the patients.

it was a prospective chart review of operated patient at hiwot fana specialized hospital for different emergency as well elective surgeries. the study subjects signed informed written consent and their data collected anonymously. the follow up protocol was until discharge from hospital the longest date as 30 days.

Eligibility criteria:
inclusion criteria: * all operated patients at surgical ward exclusion criteria: * patients operated at other facilities and transferred here. readmission within a month of discharge

Keywords: outcome
acute diverticulitis and advanced colonic neoplasia. when to perform colonoscopy (adacolon study)

Conditions: Diverticulitis, Colonic; Colonic Neoplasms

Summary: this study evaluate the prevalence of advanced colonic neoplasia (acn) in acute diverticulitis. a sub-analysis of complicated and uncomplicated acute diverticulitis will be made in order to determinate whether there are differences of advanced colonic neoplasia (anc) prevalence in both groups and to assess if a colonoscopy is necessary.

this is a prospective study that eliminates biases in the selection, design and variability of retrospective studies to reliably assess the global prevalence of advanced colon neoplasia (acn) and the difference in prevalence among populations with complicated and uncomplicated acute diverticulitis diagnosed by computed tomography. another objective is to assess the diagnostic prediction of computed tomography to detect acn in acute diverticulitis. it also aims to assess the safety and quality of colonoscopy in a patient recently diagnosed with acute diverticulitis. finally, it aims to study whether other diagnostic tools such as the presence of clinical risk symptoms or the performance of fecal biological tests could help in narrowing the indication of colonoscopy in this clinical scenario.

Eligibility criteria:
inclusion criteria: all patients consecutively diagnosed with acute diverticulitis in the participating hospitals during the study inclusion period will be included. for this purpose, a multidetector computerized tomography confirming the diagnosis of acute diverticulitis must be performed on all patients with initial clinical suspicion. exclusion criteria: 1. patient refusal to participate in the study. 2. impossibility of obtaining informed consent by the patient or guardian. 3. age \ 85 years 4. impossibility of performing a diagnostic ct of ad. 5. intercurrent medical or surgical process with prolonged recovery in time that prevents a colonoscopy before 6 months after the resolution of the episode of acute diverticulitis.

Keywords: diverticulitis advanced colonic neoplasm colonoscopy